GlassScriptPhysician profile
Sharon J Johnson
NPI 1578199204
$3,160.01
in general payments reported to CMS, 2019-2025
39 companies · $773 in 2025
The $773 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $138 · 2022: $700 · 2023: $653 · 2024: $897 · 2025: $773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,222 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,221.56 |
| Education | $101.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $352.34 | 2022-2025 | Darzalex, Erleada, Balversa |
| Incyte Corporation | $339.64 | 2021-2025 | Monjuvi, Pemazyre, Zynyz |
| Eisai INC. | $324.25 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $265.52 | 2022-2025 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $227.10 | 2022-2025 | Opdivo |
| Novartis Pharmaceuticals Corporation | $219.02 | 2022-2025 | |
| Lilly USA, LLC | $204.49 | 2022-2024 | Mounjaro |
| Celgene Corporation | $134.98 | 2022-2024 | Reblozyl |
| Amgen INC. | $130.53 | 2022 | |
| Merck Sharp & Dohme LLC | $99.76 | 2023-2025 | Keytruda, Reblozyl, Welireg |
| Genzyme Corporation | $99.04 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $86.61 | 2022 | |
| Daiichi Sankyo INC. | $66.37 | 2024 | Enhertu |
| Pharmacosmos Therapeutics INC. | $63.59 | 2024-2025 | Monoferric, Cosela |
| Takeda Pharmaceuticals U.S.A., INC. | $39.70 | 2023-2024 | Iclusig |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.